Home Featured Page 255

Featured

Latest

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Red Light Holland and Headland West Indies Lead #SVGStrong, a Relief...

Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon...

PTSF56 – Data vs. Spin, with Tim Cools of Psychedelic Experience

MindMed To Commence Trading on Nasdaq

Champignon Brands Announces Revocation of Cease Trade Orders

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin...

Aion Therapeutic’s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer...

Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the...

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create...

1...254255256...295 Page 255 of 295

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs Our Protection

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

From Huxley to Heffter: Mark Geyer Reflects on a Life in Psychedelic Research

Advanced Shadow Work and Psychedelic Integration: A Jungian Path to Wholeness

Red Light Holland and Headland West Indies Lead #SVGStrong, a Relief...

Psychedelic Bulletin: MindMed to List on Nasdaq; Atai IPO Unveiled; Champignon...

PTSF56 – Data vs. Spin, with Tim Cools of Psychedelic Experience

MindMed To Commence Trading on Nasdaq

Champignon Brands Announces Revocation of Cease Trade Orders

Silo Pharma (SILO) Announces Plans to Uplist to the NASDAQ

Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin...

Aion Therapeutic’s Proprietary Mushroom Preparations Shown Effective in Killing Breast Cancer...

Cybin Demonstrates Proof of Concept of Its Deuterated Tryptamines for the...

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create...

EDITOR PICKS

Toad, Truth, and the Trouble with 5-MeO: Why Bufo alvarius Needs...

One Year After FDA’s MDMA Rejection: Insiders and Observers Reflect

Harry Pack NFT – Last Call

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY